medigraphic.com
ISSN 0138-7103 (Print)

2016, Number S1

<< Back Next >>

Revista del Hospital Psiquiátrico de La Habana 2016; 13 (S1)

General characteristics of the main groups of Emerging Drugs: cathinones, piperazines and spices

Lajús BG

Language: Spanish
References: 26
Page:
PDF size: 98.41 Kb.


ABSTRACT

Introduction: the vast, changing and diverse group of emerging drugs, of varied origin, composition and effects of various kinds, has invaded the whole world in the twenty-first century, and as a pandemic spreads and devours the man, his family and the community, where the most vulnerable are still younger.
Objective: To increase awareness of the main groups of emerging drugs: cathinones, piperazines and spices emerged in the last five years.
Method: for it searched the Cochrane Library, MEDLINE, EMBASE, PsyclNFO, EBSCO, HINARI, Dissertation Abstracts and articles identified in their bibliographies, in addition to individual searches of MEDLINE of authors who have reported information regarding the emerging drug consumption in the last five years.
Conclusions: The severity of the emerging drug phenomenon is that of them not escape almost any country. They are therefore substances are in full and continuous evolution to sophisticated obtained by synthesis processes which, in most cases, an enigma. The information obtained is usually pseudo science that is often used as a justification for promoting the use from many websites. The virtual and globalized nature of the Internet makes it difficult to apply restrictive legal measures and their relative anonymity favors trade and distribution. Their proliferation becomes an alert for modern communities that threaten life and stability of the planet earth.


REFERENCES

  1. Bobes J y Saiz P. Editores. Monografía Drogas Recreativas. Revista Adicciones 2003;5(2).

  2. Morgan J P. Designer Drugs, en Substance Abuse, pág. 264-9. 3rd Ed. Williams & Wilkins 1997.

  3. Grob C, Poland R. MDMA, en Substance Abuse, pág 269-76. 3rd Ed. Williams & Wilkins; 1997.

  4. Mustata C, Torrens M, et al. Spice drugs: los cannabinoides como nuevas drogas de diseño. Adicciones.2009;21(3):181-6.

  5. EMCDDA (European Monitoring Centre for Drugs and Drug Addiction). Informe anual. El problema de la drogodependencia en Europa. Observatorio Europeo de las Drogas y las Toxicomanías. Lisboa [citado 12 Ene 2015]. Disponible en: www.emcdda.europa.eu/publications/annual-report/2009.

  6. Shulgin AT, Shulgin A. TIHKAL the continuation. Berkeley: Transform Press. 1997.

  7. ONU (Organización de Naciones Unidas). Oficina de las Naciones Unidas contra la Droga y el Delito (ONUDD). Informe mundial sobre las Drogas 2011. Viena [citado 12 Ene 2015]. Disponible en:www.unodc.org/unodc/en/data-and-analysis/WDR-2011.html.

  8. Naciones Unidas. Oficina contra la Droga y el Delito. Informe Mundial sobre las Drogas; 2014.

  9. Domino EF. Taming the Ketamine Tiger. Anesthesiology 2010; 113: 678-84.

  10. Vardakou I, Pistos C, Spiliopoulou Ch. Drugs for youth via internet and the example of mephedrone. Toxicol Lett 2011; 201: 191-5.

  11. Dargan P I, Albert S, Wood D M. Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM 2010; 103: 875-9.

  12. Elliott S, Smith C. Investigation of the first deaths in the United Kingdom involving the detection and quantitation of the piperazines BZP and 3-TFMPP. J Anal Toxicol 2008; 32: 172-177.

  13. Council Decision 2008/206/JHA of 3 March 2008 on defining 1-benzylpiperazine (BZP) as a new psychoactive substance which is to be made subject to control measures and criminal provisions. Official Journal of the European Union. 7 de marzo 2008. L 63/45.

  14. Ministerio de Sanidad y Política Social. Orden SAS/1916/2009, de 8 de julio, por la que se incluye la sustancia 1-benzilpiperazina (BZP) en el anexo I del Real Decreto 2829/1977, de 6 de octubre, por el que se regula la fabricación, distribución, prescripción y dispensación de sustancias y preparados psicotrópicos. Boletín Oficial del Estado Núm. 172, viernes 17 de julio de 2009.

  15. Winstock A R, Mitcheson L R, Deluca P, Davey Z, Corazza O, Schifano F. Mephedrone, new kid for the chop? Addiction 2011; 106: 154-61.

  16. Lajús G. Drogas, Adictos, Familia y Sociedad. Editora del Ministerio del Poder Popular para la Comunicación y la Información. Colección “ANÁLISIS”. Caracas, Venezuela, 2008.

  17. Lajús G. Documento Adjunto. Tesis Presentada en Opción del Grado Científico de Doctor en Ciencias Médicas. La Habana, 2010.

  18. Griffiths P, Lopes D, Sedefov R, Gallegos A, Hughes B, Noor A, et al. Khat use and monitoring drug use in Europe: the current situation and issues for the future. J Ethnopharmacol 2010; 132: 578-583.

  19. Burillo G, Domínguez A, Abreu P, Nogue S. Kath, mefedrona y dolor torácico. Med Clin (Barc) 2011.

  20. Burillo G, Balanzó X. Desmontando clichés sobre inmigración y salud. An Sist Sanit Navar 2010; 33:127-131.

  21. Fuertes M C, Elizalde l, de Andrés M R. García Castellano P, Urmeneta S, Uribe J M et al. Atención al paciente inmigrante: realidad y percepción de los profesionales de 6 zonas de Atención Primaria de Navarra. An Sist Sanit Navar 2010; 33: 57-68.

  22. Fuertes C, Trujillo E, Pinillos M, Balanzó X, Miró O, Burillo G. Atención a la diversidad en Urgencias. An Sist Sanit Navar 2010; 33 (1): 49-61.

  23. Ben M. Cannabinoids in Medicine: a Review of their potential. J. of Ethnopharmacology 2006; 105:1-25.

  24. Auwärter V, Dressen S, et al. Spice and other herbal blends: harmless incense or cannabinoid designer drugs? J of Mass Spectrometry. 2009; 44:832-837.

  25. EMCDDA (European Monitoring Centre for Drugs and Drug Addiction). Drug Profile: Synthetic Cannabinoids and Spice [citado 12 Ene 2015]. Disponible en: www.emcdda.europa.eu/publications/drugprofiles/synthetic-cannabinoids.

  26. Abanades S, Peiró A M, Farré M. Club drugs: los viejos fármacos son las nuevas drogas de la fiesta. Med Clin (Barc) 2004; 123:305-11.




2020     |     www.medigraphic.com